Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald

Group 1 - Cantor Fitzgerald raised the price target on Mirum Pharmaceuticals (MIRM) to $130 from $95, maintaining an Overweight rating on the shares [1] - Mirum's proposed acquisition of Bluejay Therapeutics is valued at $250 million in cash, $300 million in stock, and $200 million in tiered milestone payments, which is considered a "steal" by the analyst [1]